Systemic treatment for metastatic or recurrent disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Gastroesophageal (GE) adenocarcinoma is among the most solid tumor common malignancies worldwide. Despite the declining incidence, prognosis remains dismal, where the malignancy is refractory to conventional cytotoxic chemotherapy and associated with poor prognosis. While therapeutic advances over the past several years have resulted in improved patient outcomes, the observed benefits have been modest, highlighting the need for the identification and usage of novel predictive and diagnostic therapeutic targets. Advances in our understanding of the genomic alterations in key signaling pathways, genetic and epigenetic, hold promise for better treatment outcomes and improvement in patient outcomes in the near future.

Original languageEnglish (US)
Title of host publicationEsophageal Cancer
Subtitle of host publicationPrevention, Diagnosis and Therapy
PublisherSpringer International Publishing
Pages275-287
Number of pages13
ISBN (Electronic)9783030298326
ISBN (Print)9783030298319
DOIs
StatePublished - Jan 1 2019

Keywords

  • Angiogenesis
  • Gastroesophageal adenocarcinoma
  • Her-2
  • Immunotherapy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Systemic treatment for metastatic or recurrent disease'. Together they form a unique fingerprint.

  • Cite this

    Ahn, D. H., & Bekaii-Saab, T. (2019). Systemic treatment for metastatic or recurrent disease. In Esophageal Cancer: Prevention, Diagnosis and Therapy (pp. 275-287). Springer International Publishing. https://doi.org/10.1007/978-3-030-29832-6_14